| Peer-Reviewed

Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients

Received: 11 October 2022     Accepted: 31 October 2022     Published: 11 November 2022
Views:       Downloads:
Abstract

Primary open-angle glaucoma is a progressive chronic optic neuropathy, typically bilateral, that occurs after the age of 40 years. It is the second leading cause of irreversible blindness in the world. Primary open-angle glaucoma corresponds to a progressive loss of retinal ganglion cell characterized by an excavation of the optic disc associated with typical visual field defects. Objective of the study: To evaluate the impact of diabetes on the evolution of RNFL thickness and ganglion cell layer in patients followed for primary open-angle glaucoma. Materiels and methods: Our 4-year retrospective study between 2017 and 2021 included 80 patients (160 eyes) with primary open-angle glaucoma divided into 2 comparable groups: the 1st group patients primary open-angle glaucoma without type 2 diabetes mellitus (DM-) and the 2nd group patientsprimary open-angle glaucomawith type 2 diabetes mellitus (DM+). Results: The average age was 59 years for the 1st group and 62 years for the 2nd group, the sex ratio was 1.2 for the 1st group and 1 for the 2nd group, an average follow-up between 3 and 4 years. Concerning the RNFL, the loss for the diabetic group was -3.33µm/year and significantly slower than that in the group with glaucoma alone which was 3.8 µm/year with a p less than 0.001. For ganglion cells, the loss for the diabetic group was 3.2 µm/year is significantly faster than that in the group with glaucoma alone which was -1.56µm/year with a p less than 0.001. Conclusion: Diabetes probably plays a confounding role in relation to RNFL prompting vigilance in the follow-up of primary open-angle glaucoma. A larger longitudinal study with a larger sample size is needed to accurately quantify the impact on RNFL.

Published in International Journal of Ophthalmology & Visual Science (Volume 7, Issue 4)
DOI 10.11648/j.ijovs.20220704.12
Page(s) 106-110
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

POAG, RNFL, Ganglion Cells, Diabetes, Loss

References
[1] European Glaucoma Society Terminology and Guidelines for Glaucoma. (2017). -Chapter 2: Classification and terminology Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology. Br J Ophthalmol, 101 (5), 73-127. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004; 363: 1711–20.
[2] Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004; 363: 1711–20.
[3] Tham YC, Cheng CY. Associations between chronic systemic diseases and primary open angle glaucoma: an epidemiological perspective. Clin Exp Ophthalmol. 2017; 45: 24–32.
[4] Song BJ, Aiello LP, Pasquale LR. Presence and Risk Factors for Glaucoma in Patients with Diabetes. Curr Diab Rep. 2016; 16: 124.
[5] Reusch JE, Manson JE. Management of Type 2 Diabetes in 2017: Getting to Goal. JAMA. 2017; 317: 1015–1016.
[6] Quigley HA, Addicks EM, Green WR, Maumenee AE. Lésions du nerf optique dans le glaucome humain, II: le site de la blessure et la susceptibilité aux dommages. Arch Ophtalmol. 1981; 99 (4): 635–649.
[7] Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. La base moléculaire de la mort des cellules ganglionnaires rétiniennes dans le glaucome. Prog Retin Eye Res. 2012; 31 (2): 152–181.
[8] Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013; 182: 1379–90.
[9] Hernandez C, Dal Monte M, Simo R, Casini G. Neuroprotection as a Therapeutic Target for Diabetic Retinopathy. J Diabetes Res. 2016; 2016: 9508541.
[10] Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 714–20. discussion 829–30.
[11] Gordon MO, Beiser JA, Kass MA, Ocular Hypertension Treatment Study G Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol. 2008; 126: 280–1.
[12] Chopra V, Varma R, Francis BA, et al. Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study. Ophthalmology. 2008; 115: 227–232 e1.
[13] Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002; 134: 499–512.
[14] Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108: 1943–53.
[15] Drance S, Anderson DR, Schulzer M, Collaborative Normal-Tension Glaucoma Study G Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001; 131: 699–708.
[16] Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106: 2144–53.
[17] Gardiner SK, Mansberger SL. Effect of Restricting Perimetry Testing Algorithms to Reliable Sensitivities on Test-Retest Variability. Invest Ophthalmol Vis Sci. 2016; 57: 5631–5636.
[18] Abe RY, Diniz-Filho A, Zangwill LM, et al. The Relative Odds of Progressing by Structural and Functional Tests in Glaucoma. Invest Ophthalmol Vis Sci. 2016 Oct; 57: 421–8.
[19] Akkaya S, Can E, Ozturk F. Comparison of the corneal biomechanical properties, optic nerve head topographic parameters, and retinal nerve fiber layer thickness measurements in diabetic and non-diabetic primary open-angle glaucoma. Int Ophthalmol. 2016; 36: 727–36.
[20] Akkaya S, Can E, Ozturk F. Comparison of Optic Nerve Head Topographic Parameters in Patients With Primary Open-Angle Glaucoma With and Without Diabetes Mellitus. J Glaucoma. 2016; 25: 49–53.
[21] Huiyuan Hou, Takuhei Shoji, [...], and Robert N. Weinreb Progression of Primary Open Angle Glaucoma in Diabetic and Non-diabetic Patients Am J Ophthalmol. 2018 May; 189: 1–9.
[22] Kong, G. Y. X.; Van Bergen, N. J.; Trounce, I. A.; Crowston, J. G. Mitochondrial dysfunction and glaucoma. J. Glaucoma 2009, 18, 93–100.
[23] Clermont, A. C.; Bursell, S.-E. Retinal blood flow in diabetes. Microcirculation 2007, 14, 49–61.
[24] Roberts, M. D.; Grau, V.; Grimm, J.; Reynaud, J.; Bellezza, A. J.; Burgoyne, C. F.; Downs, J. C. Remodeling of the connective tissue microarchitecture of the lamina cribrosa in early experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 2009, 50, 681–690.
[25] Francis-Sedlak, M. E.; Uriel, S.; Larson, J. C.; Greisler, H. P.; Venerus, D. C.; Brey, E. M. Characterization of type I collagen gels modified by glycation. Biomaterials 2009, 30, 1851–1856.
[26] Elisaf, M.; Kitsos, G.; Bairaktari, E.; Kalaitzidis, R.; Kalogeropoulos, C.; Psilas, K. Metabolic abnormalities in patients with primary open-angle glaucoma. Acta Ophthalmol. Scand. 2001, 79, 129–132.
[27] Bonovas, S.; Peponis, V.; Filioussi, K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: A meta-analysis. Diabet. Med. 2004, 21, 609–614.
[28] Zhou, M.; Wang, W.; Huang, W.; Zhang, X. Diabetes mellitus as a risk factor for open-angle glaucoma: A systematic review and meta-analysis. PLoS ONE 2014, 9, e102972.
[29] Zhao, Y. X.; Chen, X. W. Diabetes and risk of glaucoma: Systematic review and a Meta-analysis of prospective cohort studies. Int. J. Ophthalmol. 2017, 10, 1430.
[30] Zhao, D.; Cho, J.; Kim, M. H.; Friedman, D. S.; Guallar, E. Diabetes, fasting glucose, and the risk of glaucoma: A meta-analysis. Ophthalmology 2015, 122, 72–78.
[31] Rim, T. H.; Lee, S. Y.; Bae, H. W.; Seong, G. J.; Kim, S. S.; Kim, C. Y. Increased risk of open-angle glaucoma among patients with diabetes mellitus: A 10-year follow-up nationwide cohort study. Acta Ophthalmol. 2018, 96, e1025–e1030.
[32] Kopec, J. A.; Esdaile, J. M. Bias in case-control studies. A review. J. Epidemiol. Community Health 1990, 44, 179–186.
[33] Kern, Timothy S, and Alistair J Barber. “Retinal ganglion cells in diabetes.” The Journal of physiology vol. 586, 18 (2008): 4401-8. doi: 10.1113/jphysiol.2008.156695.
Cite This Article
  • APA Style

    Soukaina Haddougui, Salma Bajjouk, Mounia Bouchaar, Mehdi Khamaily, Yassine Mouzari, et al. (2022). Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients. International Journal of Ophthalmology & Visual Science, 7(4), 106-110. https://doi.org/10.11648/j.ijovs.20220704.12

    Copy | Download

    ACS Style

    Soukaina Haddougui; Salma Bajjouk; Mounia Bouchaar; Mehdi Khamaily; Yassine Mouzari, et al. Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients. Int. J. Ophthalmol. Vis. Sci. 2022, 7(4), 106-110. doi: 10.11648/j.ijovs.20220704.12

    Copy | Download

    AMA Style

    Soukaina Haddougui, Salma Bajjouk, Mounia Bouchaar, Mehdi Khamaily, Yassine Mouzari, et al. Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients. Int J Ophthalmol Vis Sci. 2022;7(4):106-110. doi: 10.11648/j.ijovs.20220704.12

    Copy | Download

  • @article{10.11648/j.ijovs.20220704.12,
      author = {Soukaina Haddougui and Salma Bajjouk and Mounia Bouchaar and Mehdi Khamaily and Yassine Mouzari and Karim Reda and Abdelbarre Oubaaz},
      title = {Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients},
      journal = {International Journal of Ophthalmology & Visual Science},
      volume = {7},
      number = {4},
      pages = {106-110},
      doi = {10.11648/j.ijovs.20220704.12},
      url = {https://doi.org/10.11648/j.ijovs.20220704.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20220704.12},
      abstract = {Primary open-angle glaucoma is a progressive chronic optic neuropathy, typically bilateral, that occurs after the age of 40 years. It is the second leading cause of irreversible blindness in the world. Primary open-angle glaucoma corresponds to a progressive loss of retinal ganglion cell characterized by an excavation of the optic disc associated with typical visual field defects. Objective of the study: To evaluate the impact of diabetes on the evolution of RNFL thickness and ganglion cell layer in patients followed for primary open-angle glaucoma. Materiels and methods: Our 4-year retrospective study between 2017 and 2021 included 80 patients (160 eyes) with primary open-angle glaucoma divided into 2 comparable groups: the 1st group patients primary open-angle glaucoma without type 2 diabetes mellitus (DM-) and the 2nd group patientsprimary open-angle glaucomawith type 2 diabetes mellitus (DM+). Results: The average age was 59 years for the 1st group and 62 years for the 2nd group, the sex ratio was 1.2 for the 1st group and 1 for the 2nd group, an average follow-up between 3 and 4 years. Concerning the RNFL, the loss for the diabetic group was -3.33µm/year and significantly slower than that in the group with glaucoma alone which was 3.8 µm/year with a p less than 0.001. For ganglion cells, the loss for the diabetic group was 3.2 µm/year is significantly faster than that in the group with glaucoma alone which was -1.56µm/year with a p less than 0.001. Conclusion: Diabetes probably plays a confounding role in relation to RNFL prompting vigilance in the follow-up of primary open-angle glaucoma. A larger longitudinal study with a larger sample size is needed to accurately quantify the impact on RNFL.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Diabete et Primary Open-Angle Glaucoma: Comparison of RNFL Progression and Ganglion Cell Loss in Diabetic and Non-diabetic Primary Open-Angle Glaucoma Patients
    AU  - Soukaina Haddougui
    AU  - Salma Bajjouk
    AU  - Mounia Bouchaar
    AU  - Mehdi Khamaily
    AU  - Yassine Mouzari
    AU  - Karim Reda
    AU  - Abdelbarre Oubaaz
    Y1  - 2022/11/11
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijovs.20220704.12
    DO  - 10.11648/j.ijovs.20220704.12
    T2  - International Journal of Ophthalmology & Visual Science
    JF  - International Journal of Ophthalmology & Visual Science
    JO  - International Journal of Ophthalmology & Visual Science
    SP  - 106
    EP  - 110
    PB  - Science Publishing Group
    SN  - 2637-3858
    UR  - https://doi.org/10.11648/j.ijovs.20220704.12
    AB  - Primary open-angle glaucoma is a progressive chronic optic neuropathy, typically bilateral, that occurs after the age of 40 years. It is the second leading cause of irreversible blindness in the world. Primary open-angle glaucoma corresponds to a progressive loss of retinal ganglion cell characterized by an excavation of the optic disc associated with typical visual field defects. Objective of the study: To evaluate the impact of diabetes on the evolution of RNFL thickness and ganglion cell layer in patients followed for primary open-angle glaucoma. Materiels and methods: Our 4-year retrospective study between 2017 and 2021 included 80 patients (160 eyes) with primary open-angle glaucoma divided into 2 comparable groups: the 1st group patients primary open-angle glaucoma without type 2 diabetes mellitus (DM-) and the 2nd group patientsprimary open-angle glaucomawith type 2 diabetes mellitus (DM+). Results: The average age was 59 years for the 1st group and 62 years for the 2nd group, the sex ratio was 1.2 for the 1st group and 1 for the 2nd group, an average follow-up between 3 and 4 years. Concerning the RNFL, the loss for the diabetic group was -3.33µm/year and significantly slower than that in the group with glaucoma alone which was 3.8 µm/year with a p less than 0.001. For ganglion cells, the loss for the diabetic group was 3.2 µm/year is significantly faster than that in the group with glaucoma alone which was -1.56µm/year with a p less than 0.001. Conclusion: Diabetes probably plays a confounding role in relation to RNFL prompting vigilance in the follow-up of primary open-angle glaucoma. A larger longitudinal study with a larger sample size is needed to accurately quantify the impact on RNFL.
    VL  - 7
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Ophthalmology, Cheikh Khalifa Ibn Zaid International University Hospital, Casablanca, Morocco

  • Department of Ophthalmology, Cheikh Khalifa Ibn Zaid International University Hospital, Casablanca, Morocco

  • Department of Ophthalmology, Cheikh Khalifa Ibn Zaid International University Hospital, Casablanca, Morocco

  • Faculty of Medicine, University Mohamed VI of Health Sciences, Casablanca, Morocco

  • Department of Ophtalmology of the Mohamed V Military Teaching Hospital, Rabat, Morocco

  • Department of Ophtalmology of the Mohamed V Military Teaching Hospital, Rabat, Morocco

  • Department of Ophtalmology of the Mohamed V Military Teaching Hospital, Rabat, Morocco

  • Sections